U.S. Capital Wealth Advisors LLC Has $1.14 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

U.S. Capital Wealth Advisors LLC boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 213.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,484 shares of the company's stock after purchasing an additional 10,551 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in AstraZeneca were worth $1,138,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Dynamic Advisor Solutions LLC raised its stake in shares of AstraZeneca by 58.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock valued at $960,000 after acquiring an additional 4,811 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of AstraZeneca by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock valued at $32,683,000 after acquiring an additional 5,384 shares during the last quarter. Brandywine Global Investment Management LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $28,071,000. Farther Finance Advisors LLC raised its stake in shares of AstraZeneca by 13.1% in the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock valued at $442,000 after acquiring an additional 706 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of AstraZeneca by 1.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock valued at $22,903,000 after acquiring an additional 5,557 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research note on Wednesday. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, AstraZeneca currently has an average rating of "Moderate Buy" and a consensus target price of $89.00.

AstraZeneca Trading Down 0.9%

AZN traded down $0.68 during trading on Friday, reaching $71.13. 2,729,851 shares of the company's stock were exchanged, compared to its average volume of 5,279,228. The company's fifty day moving average price is $70.72 and its 200-day moving average price is $70.81. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The firm has a market capitalization of $220.60 billion, a PE ratio of 28.57, a P/E/G ratio of 1.31 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same quarter in the previous year, the business earned $2.06 EPS. The firm's revenue was up 7.2% on a year-over-year basis. As a group, equities analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.